Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions


The Risk Of Being Exposed To Europe

May 2012 | Industry Trend Analysis

BMI View: The attractiveness of Europe to pharmaceutical firms stems from the fact that its countries are key revenue sources for 'big pharma', particularly for companies selling high-end products, as per-capita spending is substantially higher than in emerging markets. However, it is BMI's view that drug companies will face many challenges in the region, particularly Western Europe, over the next decade, including the need to reduce fiscal deficits, the patent cliff, added regulatory hurdles and increasingly scrupulous cost-effectiveness assessments of new drugs. Additionally, we note that Europe is an economically heterogenic region - therefore while pharmaceutical expenditure growth will slow

To read the full article, please choose one of the following options:

Subcribers please log in

Western Europe InsightWestern Europe Channels Western Europe Countries